Callan Family Office LLC Sells 2,762 Shares of Vertiv Holdings Co (NYSE:VRT)

Callan Family Office LLC lessened its stake in shares of Vertiv Holdings Co (NYSE:VRT) by 18.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 12,227 shares of the company’s stock after selling 2,762 shares during the quarter. Callan Family Office LLC’s holdings in Vertiv were worth $1,389,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Silverleafe Capital Partners LLC bought a new stake in shares of Vertiv during the fourth quarter valued at about $4,219,000. Foundations Investment Advisors LLC boosted its holdings in Vertiv by 7.9% in the 4th quarter. Foundations Investment Advisors LLC now owns 185,512 shares of the company’s stock valued at $21,076,000 after purchasing an additional 13,559 shares during the period. Empowered Funds LLC boosted its holdings in Vertiv by 67.0% in the 4th quarter. Empowered Funds LLC now owns 9,180 shares of the company’s stock valued at $1,043,000 after purchasing an additional 3,682 shares during the period. Gordian Capital Singapore Pte Ltd boosted its holdings in Vertiv by 112.5% in the 3rd quarter. Gordian Capital Singapore Pte Ltd now owns 8,500 shares of the company’s stock valued at $846,000 after purchasing an additional 4,500 shares during the period. Finally, Nordea Investment Management AB increased its stake in Vertiv by 3,417.9% in the 4th quarter. Nordea Investment Management AB now owns 964,104 shares of the company’s stock worth $110,544,000 after acquiring an additional 936,698 shares during the last quarter. 89.92% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on VRT. TD Cowen upped their target price on Vertiv from $115.00 to $141.00 and gave the stock a “buy” rating in a research note on Tuesday, November 19th. The Goldman Sachs Group lifted their target price on shares of Vertiv from $126.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, November 19th. Citigroup lifted their target price on shares of Vertiv from $141.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Oppenheimer lifted their target price on shares of Vertiv from $121.00 to $131.00 and gave the company an “outperform” rating in a research report on Tuesday, November 19th. Finally, JPMorgan Chase & Co. increased their target price on Vertiv from $124.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, November 19th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $136.07.

Vertiv Trading Up 3.8 %

NYSE VRT opened at $85.16 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.02 and a debt-to-equity ratio of 1.19. Vertiv Holdings Co has a 1-year low of $62.40 and a 1-year high of $155.84. The firm has a market cap of $32.43 billion, a PE ratio of 66.53, a price-to-earnings-growth ratio of 1.07 and a beta of 1.71. The stock has a 50-day moving average of $115.09 and a 200-day moving average of $110.47.

Vertiv (NYSE:VRT) last issued its earnings results on Wednesday, February 12th. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.15. Vertiv had a net margin of 6.19% and a return on equity of 61.41%. During the same period in the previous year, the business earned $0.56 EPS. As a group, sell-side analysts forecast that Vertiv Holdings Co will post 3.59 EPS for the current year.

About Vertiv

Vertiv Holdings Co, together with its subsidiaries, designs, manufactures, and services critical digital infrastructure technologies and life cycle services for data centers, communication networks, and commercial and industrial environments in the Americas, the Asia Pacific, Europe, the Middle East, and Africa.